The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.
Predicting Renal, Ophthalmic And Heart Events In The Aboriginal Community: The PROPHECY Diabetes Multi-Omics Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$3,955,505.00
Summary
Diabetes is at epidemic levels in Indigenous Australians, impairing quality of life, and contributing to poor health. This is a result of rapid development of kidney, heart and eye complications. We have established a large long-term population study among Aboriginal communities within South Australia and will explore the burden, natural history and the social, psychological, environmental, clinical and genomic predictors of diabetes and its complications.
The PREDICT study will fill a very important gap in our understanding of diabetes. By studying what happens to over 3,000 people with type 2 diabetes over the next decade, it will identify improved ways of identifying which people with diabetes will develop its devastating complications. This will allow targeting of intensive treatment on those who need it the most, and will also provide an important means of identifying potential new ways of treating and supporting people with type 2 diabetes.
A Randomised Trial Of The Effects Of SGLT2 Inhibition Versus Metformin On Decline In Renal Function When Used As First Line Therapy In Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$3,815,692.00
Summary
Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.